Large Cap Archives - Page 93 of 437

2 minute read

Investors Cheer Highly Awaited Eli Lilly Earnings, Q4 Performance Surpass Expectations Thanks To Strong Zepbound Launch, Surging Weight loss Drug Sales

February 6, 9:29 AM

Eli Lilly beats Q4 2023 revenue expectations at $9.35 billion, driven by higher realized prices and strong sales of Mounjaro, Verzenio, and Jardiance.

LLY

2 minute read

Why Toyota Motor Shares Are Surging Higher Premarket Today

By Lekha Gupta

February 6, 8:49 AM

Toyota (NYSE: TM) impresses with soaring nine-month FY24 results, boasting a ¥12.04 trillion sales revenue and a 8.6% surge in retail vehicle sales to 8.564 million units. Operating income spikes to ¥1.68 trillion, fueled by strategic marketing initiatives. Toyota revises upwards its revenue and operating profit outlook for FY24.

3 minute read

Magnificent 7 Eye $13-Trillion Market Cap: ‘They Are Sucking All The Air Out Of The Universe,’ Wall Street Veteran Says

By Piero Cingari

February 5, 5:13 PM

Magnificent Seven market value surpasses $13 trillion, causing concerns about concentration in equity indices and investment portfolios.

AAPL

3 minute read

Toyota Vs. Ford — Which Motor Stock Is The Better Buy?

By Surbhi Jain

February 5, 3:27 PM

Toyota and Ford will both report earnings on Feb. 6; investors are keen to understand their contrasting market positions and focuses.

2 minute read

Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What’s Driving Markets Monday?

By Piero Cingari

February 5, 3:12 PM

Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for 2024. Treasury yields and dollar strengthen. Small-caps hit hardest.

APD

2 minute read

Why Is Animal Diagnostic-Focused IDEXX Laboratories Stock Trading Higher Today?

By Vandana Singh

February 5, 2:21 PM

IDEXX Laboratories gains on Q4 2023 results. Despite challenges, Idexx demonstrates resilience in the global animal health market.

IDXX

2 minute read

New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson’s Investigational Drug Meets Primary Goal In Two Studies

By Vandana Singh

February 5, 2:10 PM

Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG.

ARGX

2 minute read

Exxon’s Guyana Project Seen Boosting Cash Flow, Analyst Predicts Dividend Bump

By Lekha Gupta

February 5, 2:06 PM

BofA Securities analyst Doug Leggate reaffirms a Buy rating and $140 price target on Exxon Mobil (XOM) after Q4 results. Leggate sees accelerated free cash flow from key projects, expecting Exxon to surpass its 2027 cash flow goal. Anticipating strategic acquisitions, Leggate envisions a post-dividend breakeven near $40 Brent by 2024, setting the stage for robust dividend growth.

XOM

3 minute read

Alibaba Earnings: Can Q4 Earnings Provide Pivot Point For Beleaguered Investors?

By Neil Dennis

February 5, 2:01 PM

Alibaba co-founders Jack Ma and Joe Tsai have been buying shares in their company.

AMZN

1 minute read

Boeing’s 737 Turbulence – BofA Analyst Sees Light At The End Of The Runway

By Lekha Gupta

February 5, 1:55 PM

BofA Securities analyst Ronald J. Epstein maintains a Neutral rating and $225 price target on Boeing (BA). While the FAA's 737 production freeze poses challenges, Epstein believes it will enhance Boeing's long-term production efficiency, supporting mid-term market share.